Literature DB >> 7690110

Fine molecular analysis of the antigenicity of the Androctonus australis hector scorpion neurotoxin II: a new antigenic epitope disclosed by the Pepscan method.

C Devaux1, M Juin, P Mansuelle, C Granier.   

Abstract

A set of 58 overlapping rod-bound peptides was used to map the antigenic reactivity pattern of a 64-residue neurotoxin (AaH II) from the venom of the scorpion Androctonus australis hector. Five anti-toxin rabbit antisera were assayed serially for their capacity to bind to each peptide in the set. Six regions of antigenic reactivity were thus identified (sequences: 1-8, 4-12, 27-35, 39-45, 52-58 and 55-61). When positioned on a 3-D model of the toxin, these regions appeared to correspond to either beta-turn or extended parts of the molecule. The antigenic regions revealed by this technique agree fairly well with those previously mapped on the same toxin by different methods. One discrepancy was, however, that the present study shows the N-terminus to be strongly reactive with anti-toxin antibodies. The antigenicity of this region was confirmed, since rabbit antibodies raised against a synthetic peptide mimicking the sequence 1-8 of the toxin were found to bind the toxin with high efficiency. A fine analysis of the recognition of this region was performed. Alanine-containing analogs of the sequence 1-7 and peptides mimicking the N-terminal of the four main toxins of AaH were probed with anti-toxin and anti-peptide antibodies. Lysine 2, aspartic acid 3 and glycine 4 were shown to be key residues in the recognition of the N-terminal region of the AaH II toxin by anti-toxin antibodies. In contrast, a loose specificity of recognition was shown by one anti-peptide serum which was, in addition, able to recognize the N-termini of all four AaH toxins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690110     DOI: 10.1016/0161-5890(93)90152-2

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Structural insights into antibody sequestering and neutralizing of Na+ channel α-type modulator from old world scorpion venom.

Authors:  Igor P Fabrichny; Grégoire Mondielli; Sandrine Conrod; Marie-France Martin-Eauclaire; Yves Bourne; Pascale Marchot
Journal:  J Biol Chem       Date:  2012-02-27       Impact factor: 5.157

2.  Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine.

Authors:  T Takahashi; A Conforti; Y Kikumoto; D S Hoon; D L Morton; R F Irie
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

3.  Improved method for predicting linear B-cell epitopes.

Authors:  Jens Erik Pontoppidan Larsen; Ole Lund; Morten Nielsen
Journal:  Immunome Res       Date:  2006-04-24

Review 4.  Innovative Immunization Strategies for Antivenom Development.

Authors:  Erick Bermúdez-Méndez; Albert Fuglsang-Madsen; Sofie Føns; Bruno Lomonte; José María Gutiérrez; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-11-02       Impact factor: 4.546

Review 5.  Serotherapy against Voltage-Gated Sodium Channel-Targeting αToxins from Androctonus Scorpion Venom.

Authors:  Marie-France Martin-Eauclaire; Sonia Adi-Bessalem; Djelila Hammoudi-Triki; Fatima Laraba-Djebari; Pierre E Bougis
Journal:  Toxins (Basel)       Date:  2019-01-23       Impact factor: 4.546

6.  Synthetic peptides to produce antivenoms against the Cys-rich toxins of arachnids.

Authors:  Silvia A Camperi; Gerardo Acosta; Gabriela R Barredo; Lucía C Iglesias-García; Cleópatra Alves da Silva Caldeira; María C Martínez-Ceron; Silvana L Giudicessi; Osvaldo Cascone; Fernando Albericio
Journal:  Toxicon X       Date:  2020-05-05

7.  The Pharmacological and Structural Basis of the AahII-NaV1.5 Interaction and Modulation by the Anti-AahII Nb10 Nanobody.

Authors:  Riadh Hmaidi; Ayoub Ksouri; Rahma Benabderrazek; Viviane Antonietti; Pascal Sonnet; Mathieu Gautier; Balkiss Bouhaouala-Zahar; Halima Ouadid-Ahidouch
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.